November 23, 2025 a 05:00 pm
RMD: Analysts Ratings - ResMed Inc.
ResMed Inc. has shown a consistent presence in the healthcare market, primarily focusing on respiratory disorders. The latest analyst ratings show a stable interest in the company, with a majority of analysts recommending a 'Buy' stance. This positive sentiment reflects ResMed’s innovative strides in respiratory care and software services, positioning it well for future growth.
Historical Stock Grades
The latest analyst ratings for ResMed Inc. provide a snapshot of current market sentiment. As of November 2025, analysts have expressed the following recommendations:
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 3 | |
| Buy | 9 | |
| Hold | 6 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
In analyzing the sentiment, a pattern emerges where 'Buy' and 'Hold' ratings dominate the recommendations. Over recent months, there has been a slight increase in 'Hold' ratings, suggesting some caution among analysts.
- The total number of ratings has remained relatively stable over the last few months.
- A slight decrease in 'Strong Buy' and an increase in 'Hold' indicates a more cautious market sentiment.
- There remains a minimal presence of 'Sell' and 'Strong Sell' ratings, indicating confidence in the stock.
Percentage Trends
The percentage distribution of these ratings shows minimal shifts, with the most notable changes being a slight reduction in 'Strong Buy' and an increase in 'Hold'. This trend points towards analysts exhibiting cautious optimism:
- 'Strong Buy' has decreased from 14.3% to 12.0% over the past year.
- 'Buy' remains stable around 36.0% to 40.0%.
- 'Hold' has increased slightly, suggesting more reserved confidence.
Latest Analyst Recommendations
The latest recommendations continue to reflect general consistency in opinion among analysts, with a large proportion of recommendations maintaining previous ratings.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-11-03 | Outperform | Outperform | Baird |
| 2025-10-31 | Outperform | Outperform | Mizuho |
| 2025-10-31 | Outperform | Outperform | RBC Capital |
| 2025-10-31 | Overweight | Overweight | Keybanc |
| 2025-10-21 | Overweight | Overweight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
Over the last year, changes in recommendations have been few, but notable, primarily involving upgrades which reflect a cautious shift towards optimism.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-07-16 | Outperform | Sector Perform | RBC Capital |
| 2025-03-05 | Buy | Neutral | Citigroup |
| 2024-09-18 | Underperform | Peer Perform | Wolfe Research |
| 2024-09-04 | Hold | Buy | Needham |
| 2024-06-25 | Perform | Outperform | Oppenheimer |
Interpretation
The market's view on ResMed Inc. shares is cautiously optimistic. Current analyst sentiment suggests stable confidence in their medical innovations and software services. However, the slight rise in 'Hold' ratings might imply some hesitancy about either recent performance or future outlooks. The general stability in recommendations with few downgrades or upgrades reflects a consistent level of belief in the stock’s valuation.
Conclusion
In summary, ResMed Inc. remains a strong entity in healthcare technology, reflected by predominantly positive analyst ratings. While the slight shift in sentiment suggests marginal caution, the stability in recommendations reflects a steadfast belief in the company's potential. With consistent performance and innovative offerings, ResMed continues to present a promising outlook, though some caution may be advised. Investors may want to monitor future developments closely to assess any changes in sentiment or performance.